Jones Soda, the irreverent maker of soda and juice beverages, said Friday that the Seattle company will be listed on the Nasdaq SmallCap Market starting Nov. 28.

Share story

Pacific Northwest


Jones Soda, the irreverent maker of soda and juice beverages, said Friday that the Seattle company will be listed on the Nasdaq SmallCap Market starting Nov. 28.


Its stock will trade under the ticker JSDA.


The company is currently listed on the OTC Bulletin Board, where its shares closed unchanged Friday at $5.30.


“When you’re on the [OTC] Bulletin Board, your objective is moving up to the majors,” said Jones Soda President and Chief Executive Peter van Stolk. “Jones Soda has been in the minors and now we’ve been called up to the majors. We’re really excited for that.”


Jones Soda reported a profit of $702,781, or 3 cents a share, on sales of $24.8 million for the nine months ended Sept. 30.


The company also announced that Jennifer Cue, its chief financial officer, chief operating officer and a board director, resigned from all her positions Monday. The company gave no reason for her resignation, but said it has initiated a replacement search.


Nextel Partners

Company claims “complete victory”


Nextel Partners said a court ruling Friday dealing with several issues related to how a takeover of the Kirkland company by Sprint Nextel would be completed was a “complete victory.”


Nextel Partners’ shareholders voted to sell the company to Sprint Nextel based on a right given to them if there were ever a change in control of Nextel Communications.


The hearing in Delaware Chancery Court addressed how Nextel Partners will be valued. Nextel Partners said the court agreed that shareholders would be able to see the value that appraisers, selected by each side, assigned to the company, and that the definition of “fair-market value” should be interpreted by the appraisers.


Infinium Labs

Consultant replaces CEO


Xbox co-founder Kevin Bachus resigned Thursday as chief executive, president, acting chief financial officer and director of Infinium Labs, a troubled Seattle company developing a video-gaming system.


In a regulatory filing Friday, Infinium said its board has hired Greg Koler to replace Bachus effective immediately. Koler had been a full-time consultant for the company since June 2004.


Bachus wouldn’t give further details about the resignation when contacted Friday. He said he is pursuing other opportunities, which he plans to announce soon.

ID Biomedical

Shareholders OK acquisition


Shareholders in ID Biomedical, the Canadian vaccine maker with more than 100 employees in Bothell, have approved a $1.4 billion acquisition by GlaxoSmithKline.


The deal, favored by nearly 85 percent in a vote Wednesday, was announced in September and still needs approval from Canadian authorities. No word yet on plans for the Bothell operation.


Compiled from Seattle Times staff